Bazedoxifene acetate: Selective estrogen receptor modulator treatment and prevention of osteoporosis

Drugs of the Future

Volumn 27, Issue 2, 2002, Pages 117-121

  Miller, Chris P ^a   Harris, Heather A ^a   Komm, Barry S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; LASOFOXIFENE; LIVER TRIACYLGLYCEROL LIPASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOEQUIVALENCE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DNA SEQUENCE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIGAND BINDING; LIPID METABOLISM; OSTEOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROMOTER REGION; PROTEIN CONFORMATION; TRANSCRIPTION REGULATION; UTERUS;

EID: 0036244170     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.02.637843     Document Type: Article

References (25)

1. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens
2. Estrogen receptors: Orchestrators of pleiotropic cellular responses
3. The multifaceted mechanisms of estradiol and estrogen receptor signaling
4. The mechanism of action of steroid hormone receptors
5. Nuclear receptor coregulators: Cellular and molecular biology
6. 4-Hydroxytamoxifen trans-represses nuclear factor-κ B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)α, and not through ER β
7. A novel human estrogen receptor β: Identification and functional analysis of additional N-terminal amino acids
8. Estrogen effects in the myocardium: Inhibition of NF-κB DNA binding by estrogen receptor-α and -β
9. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site
10. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
11. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
12. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
13. Effects of anti-estrogens on bone in castrated and intact female rats
14. Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen
15. A pharmacological review of selective oestrogen receptor modulators
16. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy
17. Designer estrogens. Getting all of the benefits, few of the risks
18. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1 H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotrophic effects in mice and rats
19. Clinical efficacy of raloxifene in postmenopausal women
20. Effects of raloxifene hydrochoride on the endometrium of postmenopausal women
21. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
22. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation
23. TSE-424, a novel selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion